AstraZeneca Sheds £19bn as Heart-Drug Trial Fails
AstraZeneca shares fell as much as 9% in London — wiping around £19bn from the value of Britain’s largest listed company — after a late-stage trial of its heart drug Wainua, developed with the US firm Ionis, failed to reduce deaths and cardiac events in patients with a form of heart failure. Ionis shares dropped around 20%. The setback dragged the FTSE 100 lower on a day already unsettled by the Gulf war.
A rare research failure for a national champion matters beyond one drug: AstraZeneca is the single heaviest weight in the FTSE 100, so its stumble moves the index millions of British pension pots track, and it dents the credibility of an ambitious sales target the company has staked on its pipeline. Analysts were quick to say the wider goal is not derailed — a benefit was seen in some patients — but a missed primary endpoint in a marquee cardiovascular trial is the kind of miss that resets expectations. It lands as the war’s oil premium already pressures the market. Watch the read-across to Ionis, the drug’s existing licences, and whether the sell-off deepens.